1. Turkey Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

BBIST:ECILC
50.15
TRY
-1.75
(-3.37%)
-2.44EPS
51.33BMarket Cap
EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
BIST:ECILC
(Istanbul Exchange)

Recent

price

50.15

P/E

ratio

- -

div

yld

-0.71%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TRY
1.33
1.42
1.29
1.64
1.53
1.93
0.78
0.87
1.01
1.28
1.33
1.61
5.06
13.65
16.75
14.4
14.88
Revenue per Share
0.09
0.13
0.05
0.09
-0.06
0.11
0.27
0.21
0.35
0.24
0.47
1.84
4.35
5.77
1.96
3.05
-2.44
Basic EPS, GAAP
-0.03
-0.01
0.06
-0.06
0.02
0.06
0.22
0.12
0.26
0.24
0.1
0.72
-1.81
3.11
3.08
1.62
0.72
Free Cash Flow per Basic Share
0.06
0.06
0.08
0.08
0.08
0.07
0.32
0.5
0.2
0.3
0.07
0.22
0.58
0.98
1.79
1.99
-0.35
Dividend per Share
3.46
3.8
4.17
4.2
4
3.99
4.74
5.08
5.83
6.24
9.35
13.18
45.59
73.41
85.73
89.08
100.42
Book Value per Share
3.42
3.78
4.07
4.1
3.92
3.91
4.66
5.06
5.81
6.22
9.34
13.15
43.46
70.47
81.95
85.61
95.83
Tangible Book Value per Share
685
685
685
685
685
608
675
685
685
685
685
685
685
685
685
685
685
Basic Weighted Avg Shares
913
974
887
1,126
1,047
1,171
530
598
692
877
909
1,104
3,466
9,355
11,476
9,871
10,199
Sales/Revenue/Turnover
5.55
2.07
0.83
0.85
-1.48
0.39
10.91
9.05
7.73
14.51
12.7
8.34
2.06
3.79
-1.18
-9.34
-7.1
Operating Margin (%)
19
21
11
14
19
18
21
10
10
21
23
20
177
738
977
934
893
Depreciation Expense
60
89
34
61
-43
68
185
146
240
163
322
1,264
2,983
3,956
1,340
2,089
-1,670
Net Income, GAAP
19.21
25.43
18.29
33.32
- -
25.35
13.87
16.47
18.68
15.74
16.54
16.04
13.8
11.68
31.46
29.99
- -
Effective Tax Rate (%)
6.61
9.09
3.88
5.45
-4.14
5.78
34.86
24.43
34.69
18.55
35.43
114.51
86.07
42.28
11.68
21.16
-16.38
Profit Margin (%)
782
745
725
723
659
614
561
531
671
643
853
1,254
2,186
2,985
5,013
4,858
2,494
Working Capital
- -
- -
- -
- -
31
63
32
15
48
18
50
31
2,464
2,700
2,222
1,053
1,426
LT Debt
2,387
2,614
2,906
2,920
2,761
2,740
3,244
3,481
3,998
4,277
6,410
9,032
31,241
50,312
58,755
61,044
68,818
Total Equity
1.79
0.32
0.55
3.04
- -
3.14
4.46
3.08
4.47
4.48
4.53
7.38
4.45
2.56
1.07
0.78
- -
Return on Invested Capital (%)
2.52
3.49
1.35
2.47
- -
3.56
6.5
4.29
6.77
4.46
6.27
16.37
14.26
11.25
3.66
4.26
- -
Return on Capital (%)
2.66
3.56
1.26
2.14
-1.54
2.47
6.17
4.34
6.42
3.93
6.03
16.36
14.82
9.7
2.46
3.49
-2.74
Return on Common Equity (%)

Capital Structure

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,109
2,521
2,528
LT Borrowings
904
1,241
1,312
LT Finance Leases
149
130
114
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
685
685
685
Market Capitalization
56,054
71,815
51,326

Working Capital

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,674
9,387
7,774
Cash, Cash Equivalents & STI
4,848
4,048
2,489
Accounts Receivable, Net
2,269
2,730
2,351
Inventories
2,164
2,017
2,448
Total Current Liabilities
4,816
5,428
5,280
Payables & Accruals
- -
- -
- -
ST Debt
2,109
2,521
2,528
Deferred Revenue
- -
- -
- -

Growth Rates

TRY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.59%
73.7%
3.9%
Free Cash Flow
21.99%
-15.13%
-47.38%
Net Income, GAAP
73.31%
90.15%
55.9%
Sales/Revenue/Turnover
41.83%
82.81%
-13.98%
Total Cash Common Dividend
90.37%
106.71%
11.4%

Quarterly Revenue

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,864
2,232
2,776
2,436
11,476
2025
2,784
2,746
2,251
2,961
9,871
2026
2,747
2,239
- -
- -
- -

Quarterly Earnings Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.91
-0.67
1.48
0.15
1.96
2025
2.94
0.58
0.72
-0.7
3.05
2026
-1.35
-1.11
- -
- -
- -

Quarterly Dividends Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.12
0.08
1.79
2025
- -
- -
-0.44
0.08
1.99
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. (ECILC.IS) operates as a holding company focused on health and real estate development sectors in Turkey and internationally. Founded in 1951 and headquartered in Istanbul, Turkey, the company functions through its subsidiaries and affiliates, including Eczacibasi Ilac Ticaret A.S., EHP Eczacibasi Health Care Products Joint Stock Co., and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S.; its health segment produces and sells human health medicines such as cephalosporins and penicillins, veterinary drugs, and personal care products including body and facial creams, hair gels, and deodorants; the real estate development segment develops properties, leases serum facilities, and provides land development and project management consulting services. As a subsidiary of Eczacibasi Holding A.S., it maintains a holding structure without direct production activities, instead acting as a strategic partner in healthcare, building products, and other industries while directly engaging in real estate development. Recent developments include a 2025 ordinary general assembly resolution for compliance with Turkish Commercial Code and Capital Markets Law, alongside historical strategic shifts such as the 2007-2009 transfer of shares in health product subsidiaries to Zentiva N.V. and a 2008 name change to its current title, with ongoing investments like increased stakes in affiliates such as Eczacibasi-Monrol Nükleer. The company lists on Borsa Istanbul with 18.76% free float and exports pharmaceuticals to the Middle East, Russian Federation, Central Asia, and Eastern Europe.